Screener
ImmunityBio, Inc. IBRX Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InventoryNoncurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 452,953 | 314,875 |
| Property, plant and equipment, net | 112,785 | 114,264 |
| Goodwill and intangible assets, net | 12,885 | 13,953 |
| Long-term inventories | 18,856 | 13,508 |
| Convertible note receivable | — | 7,380 |
| Operating lease right-of-use assets, net | 20,573 | 19,808 |
| Operating lease right-of-use assets, net – related parties | 12,461 | 13,202 |
| Other assets | 15,746 | 4,530 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s inventories?
- ImmunityBio, Inc. (IBRX) reported inventories of $18.86M in Q1 2026.
- How has ImmunityBio, Inc.'s inventories changed year-over-year?
- ImmunityBio, Inc.'s inventories increased by 123.3% year-over-year, from $8.44M to $18.86M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about ImmunityBio, Inc.'s inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude